Classement en actions
#2736
Metsera, Inc. operates as a clinical-stage biotechnology firm, specializing in... Metsera, Inc. operates as a clinical-stage biotechnology firm, specializing in crafting both injectable and oral nutrient-stimulated hormone analog peptides. These therapeutic compounds are primarily aimed at addressing obesity, overweight conditions, and associated health issues. Its developmental pipeline features MET-097i and MET-233i, both under investigation for treating obesity and overweight patients. Furthermore, Metsera is advancing a potential combination therapy involving MET-233i and MET-097i. The company is also progressing additional drug candidates, including MET-002, MET-224o, MET-067i, and MET-034i, all of which target disorders such as diabetes and obesity. Founded in 2022, Metsera, Inc. maintains its corporate headquarters in New York, New York.
Prix de l'action
$70.50
Dernière synchronisation: 2025-11-14
Capitalisation boursière
$7.33B
Changement (1 jour)
0.00%
Changement (1 an)
116.32%
Échange Metsera, Inc. (MTSR)
Le prix MTSR avec la capitalisation boursière de B
Capitalisation boursière de Metsera, Inc.(MTSR)
Capitalisation boursière: $7.33B
En August 2026, Metsera, Inc. a une capitalisation boursière de $7.33B. Cela fait de Metsera, Inc. la 2736th entreprise la plus valorisée au monde selon nos données. La capitalisation boursière, souvent appelée market cap, correspond à la valeur totale des actions en circulation d’une entreprise cotée en bourse, et est couramment utilisée pour évaluer sa valeur.
Historique de la capitalisation boursière de Metsera, Inc. du 2025 au 2026
MTSR par rapport au top 5 des plus populaires stocks
| Prix pour MTSR |
|
L’actif B |
La capitalisation boursière de B |
Résultats |
|
|
|
|
$5.154T
|
+70,221.56%
|
|
|
|
|
$4.540T
|
+61,845.83%
|
|
|
|
|
$4.164T
|
+56,719.69%
|
|
|
|
|
$3.641T
|
+49,580.99%
|
|
|
|
|
$2.803T
|
+38,141.36%
|
